PharmaCyte Biotech Inc
PMCB - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.24M
Close$
$2.07
557.1% upside
Current Fair Value
557.1% upsideUndervalued by 557.1% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $3.24 Million |
|---|---|
| Enterprise Value | $-14,495,766.00 |
| Earnings per Share | $-2.77 |
| Beta | 0.68 |
| Outstanding Shares | 10,735,649 |
Return
| Return on Equity | -58.32% |
|---|---|
| Return on Assets | -46.70% |
| Return on Invested Capital | -15.20% |
Valuation & Multiples
| P/E Ratio | -0.13 |
|---|---|
| PEG | 0.32 |
| Price to Sales | - |
| Price to Book Ratio | 0.16 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 2.65 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
September 14, 2026
EPS Estimate
$-0.06
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
December 16, 2026
EPS Estimate
$-0.06
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%▼ 10.87% |
|---|---|
| Total Invested | $4▼ 100.00% |
| Investors Holding | 2▼ 26.00% |
About PharmaCyte Biotech Inc
4 employees
PharmaCyte Biotech, Inc. is a biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as "Cell-in-a-Box®." This technology is being use...